

BOSTON SCIENTIFIC CORP
Form 8-K
May 06, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **May 5, 2015**

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other
jurisdiction of
incorporation)

1-11083
(Commission
file number)

04-2695240
(IRS employer
identification no.)

300 Boston Scientific Way, Marlborough, Massachusetts
(Address of principal executive offices)

01752-1234
(Zip code)

Registrant's telephone number, including area code: **(508) 683-4000**

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

(a) Boston Scientific Corporation (the Company) held its 2015 Annual Meeting of Stockholders (the Annual Meeting) on May 5, 2015 at its Corporate Headquarters located in Marlborough, Massachusetts.

(b) The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

(1) All eleven director nominees were elected to the Company's Board of Directors for a one-year term to hold office until the Company's 2016 Annual Meeting of Stockholders and until their successors have been elected and qualified.

| Nominee | For | Withheld | Broker Non-Votes |
|------------------------|---------------|-------------|------------------|
| Nelda J. Connors | 1,100,607,449 | 17,045,045 | 56,352,573 |
| Charles J. Dockendorff | 1,106,857,157 | 10,795,337 | 56,352,573 |
| Kristina M. Johnson | 1,101,047,615 | 16,604,879 | 56,352,573 |
| Edward J. Ludwig | 1,102,566,527 | 15,085,967 | 56,352,573 |
| Stephen P. MacMillan | 1,097,304,916 | 20,347,578 | 56,352,573 |
| Michael F. Mahoney | 1,103,435,990 | 14,216,504 | 56,352,573 |
| Ernest Mario | 716,615,095 | 401,037,399 | 56,352,573 |
| N.J. Nicholas, Jr. | 971,605,297 | 146,047,197 | 56,352,573 |
| Pete M. Nicholas | 1,095,195,859 | 22,456,635 | 56,352,573 |
| David J. Roux | 1,102,085,411 | 15,567,083 | 56,352,573 |
| John E. Sununu | 1,100,206,409 | 17,446,085 | 56,352,573 |

(2) The advisory vote on the compensation for the Company's Named Executive Officers as disclosed in the Company's proxy statement for the Annual Meeting (the Proxy Statement) was approved.

| For | Against | Abstain | Broker Non-Votes |
|---------------|------------|-----------|------------------|
| 1,099,762,641 | 15,075,270 | 2,814,583 | 56,352,573 |

(3) The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2015 fiscal year was ratified.

| For | Against | Abstain | Broker Non-Votes |
|---------------|------------|-----------|------------------|
| 1,162,172,501 | 10,444,359 | 1,388,207 | N/A |

(4) The stockholder proposal regarding accountability in animal use as described in the Proxy Statement was not approved.

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

| For | Against | Abstain | Broker Non-Votes |
|------------|----------------|----------------|-------------------------|
| 31,831,102 | 836,036,432 | 249,784,960 | 56,352,573 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

Date: May 6, 2015

By: */s/ Vance R. Brown*
Vance R. Brown
Vice President and Chief Corporate Counsel